Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain MacIntyre

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Urology|June 30, 2025
Effect of Sex Differences on Cancer Outcomes After Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort StudyIain MacIntyre, Ronald Kool, Gautier Marcq, et al.
Journal of Human Hypertension|June 28, 2024
Investigation and management of young-onset hypertension: British and Irish hypertension society position statementSpoorthy Kulkarni, Luca Faconti, Sarah Partridge, et al.
American Heart Journal|September 11, 2017
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trialManvir K Hayer, Nicola C Edwards, Gemma Slinn, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Urology|June 30, 2025
Effect of Sex Differences on Cancer Outcomes After Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort StudyIain MacIntyre, Ronald Kool, Gautier Marcq, et al.
Journal of Human Hypertension|June 28, 2024
Investigation and management of young-onset hypertension: British and Irish hypertension society position statementSpoorthy Kulkarni, Luca Faconti, Sarah Partridge, et al.
American Heart Journal|September 11, 2017
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trialManvir K Hayer, Nicola C Edwards, Gemma Slinn, et al.
Pageof 3